Tab navigation

About the event 简介

Chronic conditions are increasing across the world, not least in China. With a quickly ageing population and a switch to post-industrial lifestyles, incidents of critical diseases such as cancer are rising rapidly. The government is responding with reforms, including the 'Healthy China' 2030 vision statement.

These reforms have also seen the suggestion of new definitions of critical illness insurance. This has attracted widespread attention within the insurance industry. Insurers are seeking to engage with the government, health care providers, academia and other stakeholders to ensure better protection for policy holders and greater resilience within society.

In an economy with low health insurance penetration, developing critical illness insurance is a key priority for insurers in the Chinese market. It prompts a number of questions, including: How are cancer trends in China developing? What is the impact of early screening policies? How effective are anti-cancer vaccines? How does diet affect cancers of the digestive tract? Can insurers provide cancer products with innovative lifestyle solutions? What is the latest data on product pricing and what are the lessons that can be learned from critical illness products in other markets?

Swiss Re Institute is organising a Critical Illness Insurance eForum series with insurance experts from Swiss Re, leading researchers and health industry professionals. Held exclusively in Chinese, the event will address topics of key relevance in the development of critical illness products and their contribution to societal resilience. As a highly trusted re/insurance partner, Swiss Re is seeking to work closely with customers and partners to close the health protection gap and promote the sustainable development of the critical illness insurance market in China.

 

重疾在中国乃至全球仍然是备受关注的健康话题之一。随着中国人口的快速老龄化和生活方式的演变,癌症等重大疾病对人们健康的影响也更加不容忽视,“健康中国2030”也已成为重要的国家健康战略。与此同时,正在调整中的重疾险新定义也引起了行业的广泛关注。为更好地应对重疾风险,为社会提供更好的保障,政府、行业和学界都在不断探索解决之道。

对于保险公司来说,在新形势下推动重疾险业务的健康发展已成为当务之急,并面临诸多课题和挑战。癌症在中国的发展趋势如何?早期筛查及疫苗对癌症有什么影响和意义?生活方式对消化道肿瘤有什么影响?如何使生活方式与保险产品创新更好地结合?针对产品定价有哪些新发现及其影响如何?国际市场有哪些相关经验及重疾模型可以借鉴?

瑞再研究院组织了由瑞士再保险的专家团队、研究机构的医学专家及行业同仁共同参与的重疾险系列论坛,就上述话题展开广泛而深入的交流,探讨中国在应对重疾风险、增强社会韧性方面的机遇与挑战。作为值得信赖的保险合作伙伴,瑞士再保险对中国市场充满信心,并将与广大客户及合作伙伴携手合作,共同为缩小健康保障缺口和推动重疾险在中国的可持续发展做出努力。

Contact

Discover more Swiss Re China Cancer Forum

From vision to resilience towards Healthy China 2030

Discover

Related teasers

  • Conference ​Insurance Management Simulation